Diagnosis Is Beside the Point
Some of the thorniest problems in medicine that AI can improve have nothing to do with diagnosis. They have to do with triage.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But Vertex Pharmaceuticals could also compete with a drug candidate from a recent acquisition.
Allswell Raises $7M to Grow LGBTQ+ Behavioral Health Platform
Allswell's seed round was led by Rethink Impact, and included participation from Magnify Ventures, Ulu Ventures and Hopelab Ventures, joining existing investors Techstars and Amboy Street Ventures.
The Antibiotics Exist —The System Cannot Deliver Them
This is not a discovery problem. It is a market entry and access problem, and it is far more tractable than the pipeline crisis we spend most of our attention on.
Exercise is Prescribed Like Advice When It Should Be Delivered Like Treatment
Health care routinely recommends movement without providing assessment, dosage, progression, and follow-up that turn good advice into usable care.